Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tailored thrombolytic therapy. A perspective

M L Simoons1, A E Arnold

  • 1Thoraxcenter, Erasmus University, Rotterdam, The Netherlands.

Circulation
|December 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effects of a Perindopril-Based Regimen in Relation to Statin Use on the Outcomes of Patients with Vascular Disease: a Combined Analysis of the ADVANCE, EUROPA, and PROGRESS Trials.

Cardiovascular drugs and therapy·2022
Same author

Vertically transmitted microbiome protects eggs from fungal infection and egg failure.

Animal microbiome·2021
Same author

Molecular lemmings: strategies to avoid when designing BODIPY ferrocene dyads for dye-sensitized solar cell applications.

Dalton transactions (Cambridge, England : 2003)·2018
Same author

The Treatment Effect of an ACE-Inhibitor Based Regimen with Perindopril in Relation to Beta-Blocker use in 29,463 Patients with Vascular Disease: a Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS Trials.

Cardiovascular drugs and therapy·2017
Same author

Erratum to: Interaction type influences ecological network structure more than local abiotic conditions: evidence from endophytic and endolichenic fungi at a continental scale.

Oecologia·2016
Same author

Chemical constituents and their antibacterial activity from the tropical endophytic fungus Diaporthe sp. F2934.

Journal of applied microbiology·2016
Same journal

A Bundle to Frame Guidelines and American Heart Association Statements.

Circulation·2026
Same journal

<i>Circulation</i> Editors and Editorial Board.

Circulation·2026
Same journal

A New <i>Circulation</i>, For You.

Circulation·2026
Same journal

Cardiovascular Risk Reduction With GLP-1 RA Drugs.

Circulation·2026
Same journal

Obesity, Severe Obesity, and Abdominal Obesity in US Youth and Adults From 1999 to 2023.

Circulation·2026
Same journal

Lipid Profile Testing and Interpretation.

Circulation·2026
See all related articles

Tailoring thrombolytic therapy to individual patient profiles optimizes treatment. Models predict benefits and risks, guiding personalized therapeutic choices to improve outcomes and reduce bleeding complications.

Area of Science:

  • Cardiology
  • Pharmacology
  • Medical Informatics

Background:

  • Current thrombolytic therapy often uses standard regimens.
  • Tailoring treatment to individual patient characteristics is proposed as a more appropriate approach.
  • A model for personalized thrombolytic therapy involves assessing individual benefits and risks.

Purpose of the Study:

  • To present a model for tailoring thrombolytic therapy based on individual patient characteristics.
  • To estimate potential benefits and risks of thrombolysis for personalized treatment selection.
  • To guide decisions on continuing, intensifying, or discontinuing thrombolytic therapy based on real-time patient response.

Main Methods:

  • Utilizing demographic data (age, sex, infarction history) and ischemic indicators (ST deviation, delay) to predict thrombolysis benefits.

Related Experiment Videos

  • Estimating intracranial hemorrhage risk using patient age, blood pressure, and weight.
  • Employing continuous ECG monitoring and cardiac protein assays to assess reperfusion and reocclusion.
  • Developing benefit/risk models to select appropriate thrombolytic efficacy regimens (high, medium, modest).

    • Main Results:

    • Models can estimate "lives saved" and bleeding risks based on patient-specific factors.
    • Personalized dose adjustments can reduce bleeding complications.
    • Real-time monitoring allows for dynamic modification of thrombolytic therapy.
    • Tailored approaches enable selection between different levels of thrombolytic efficacy.

    Conclusions:

    • The presented models for benefit/risk assessment in tailoring thrombolytic therapy require clinical validation.
    • Testing these models in clinical studies is crucial for physician adoption.
    • This approach aims to optimize therapeutic strategies for individual patients.